AVE 33.3% 0.2¢ avecho biotechnology limited

oxymorphone patch m eets phase 1 end points, page-27

  1. 5,763 Posts.
    lightbulb Created with Sketch. 309
    a potential buyer has indicated to us that they would be willing to put an offer on the table after seeing phase 2 results, so for the minimal extra time and cost involved we considered it not a bad bet.

    Interesting theory JM. Could this same theory be applied to OxyC after multidose?

    It makes sense cost wise and time and resourse wise. But at the risk of being caught out with time and cost if doesnt pan out that way then having to do phase 3 seperate.

    More than one way to fry a deal I guess.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.